Sixty-five postmenopausal patients with metastatic or surgically unresectable primary breast cancer, all estrogen receptor (ER) positive, were treated with tamoxifen 20–40 mg a day. Overall objective response rate was 58%, with a median duration time of 13 months. The correlation between response rate and ER levels appears positive, although not statistically significant. The analysis of the data was also performed in the subgroups « locally advanced tumors » and « recurrences and metastases ».
Get full access to this article
View all access options for this article.
References
1.
AllegraJ.C.LippmanM.E.: Estrogen receptor determination predicts response to tamoxifen therapy.In: Endocrine Treatment of Breast Cancer, Edited by HemingsensB.LinderF.SteicheleC. pp. 16–19, Springer-Verlag, Berlin-Heidelberg-New York, 1980.
2.
Di FronzoG.BertuzziA.RonchiE.: An improved criterion for the evaluation of the estrogen receptor binding data in human breast cancer.Tumori, 64: 259–266, 1978.
3.
HaywardJ.L.CarboneP.P.HeusonT.C.KumaokaS.SegaloffA.RubensR.D.: Assessment for response to therapy in advanced breast cancer.Cancer, 39: 1289–1294, 1977.
4.
KiangD.T.KennedyB.J.: Tamoxifen (antiestrogen) therapy in advanced breast cancer.Ann. Intern. Med., 87: 687–690, 1977.
5.
ManniA.TrujilloJ.E.MarshallJ.S.BrodkeyJ.PearsonO.H.: Antihormone treatment of stage IV breast cancer.Cancer, 43: 444–450, 1979.
6.
McGuireW.L.HorwitzK.B.PearsonO.H.SegaloffA.: Current status of estrogen and progesterone receptors in breast cancer.Cancer, 39: 2934–2947, 1977.
7.
MosesonD.L.SasakiG.H.KraybillW.G.LeungB.S.DavenportC.E.FletcherW.S.: The use of antiestrogens, tamoxifen and nafoxidine in the treatment of human breast cancer in correlation with estrogen receptor values.Cancer, 41: 797–800, 1978.
8.
MouridsenH.T.PalshofT.PattersonJ.BattersbyL.: Tamoxifen - a review of its efficacy in advanced breast cancer.Cancer Treat. Rev., 5: 131–141, 1978.
9.
RoseC.ThorpeS.M.LoberJ.L.DaenfeldtT.PalshofT.MouridsenH.T.: Therapeutic effect of Tamoxifen related to estrogen receptor level.In: Endocrine Treatment of Breast Cancer, Edited by HemingsensB.LinderF.SteicheleC. pp. 134–141, Springer-Verlag, Berlin-Heidelberg-New York, 1980.
